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Summary Proliferation of drug resistant tumour following chemotherapy is the principal cause of treatment
failure in small cell lung cancer (SCLC). Verapamil has been shown to partially restore drug sensitivity in
tumour cells rendered resistant in vitro. The results of the first large-scale randomised study of a resistance
modifying drug given in conjunction with chemotherapy in cancer patients are reported.
Two hundred and twenty-six patients have been entered. All patients received four cycles of cyclophos-
phamide (750 mg m-2), doxorubicin (40 mg m-2) and vincristine (1.4 mg m-2) on Day 1 and etoposide
(75 mg m-2) on Days 1, 2 and 3, repeated at 21 day intervals. Those patients randomised to the verapamil arm
received oral verapamil 120 mg qid for 5 days with each course of chemotherapy. Similar numbers of cycles of
protocol treatment were given in both arms with over 75% of patients completing all four cycles.
There were no significant differences in general toxicities between the two arms, except for more severe
alopecia in the verapamil treatment group (P = 0.045). There was no significant difference in cardiovascular or
haematological toxicity, although the median nadir white cell count after Cycle 1 chemotherapy was lower in
the verapamil arm (P = 0.065) and there were significantly more dose reductions after Cycle 1 in the verapamil
arm (P = 0.031). No statistically significant differences in response (P = 0.582) or survival (P = 0.290) data
were seen.
The absence of a significant improvement in response or survival using verapamil may relate to the low
blood levels of verapamil seen in the clinic (0.8gM), in contrast to those known to be maximally active in vitro
(>6 pM) or to the presence of other cellular mechanisms by which drug resistance develops.
The emergence of drug resistant tumour following chemo-
thertkpy is the principal cause of treatment failure in small
cell lung cancer (SCLC). Verapamil has been shown to par-
tially restore the drug sensitivity of tumour cells rendered
resistant in vitro by chronic exposure to cytotoxic drugs
(Tsuruo et al., 1982). Such cells demonstrate a pattern of
cross-resistance to a specific group of cytotoxic drugs
(anthracyclines, vinca alkaloids and podophyllotoxins) and
are known to contain a membrane energy-dependent cyto-
toxic drug efflux pump (P-glycoprotein) which is thought to
confer drug resistance. The activity of verapamil in such
multidrug resistant (MDR) tumour cells relates to inactiva-
tion of the P-glycoprotein pump. This effect is known to be
dose dependent (Plumb et al., 1990).
There have been few clinical studies to examine the activity
of resistance modifying drugs but pilot clinical studies have
shown some responses in pre-treated patients given various
verapamil schedules in addition to further chemotherapy
(Dalton et al., 1989; Presant et al., 1986). In these studies the
dose limiting toxicity was cardiac (Benson III et al., 1985;
Ozols et al., 1987; Presant et al., 1986). To date only one
non-randomised study (Figueredo et al., 1990) has suggested
survival benefit from the addition of resistance modifier.
Thus, the majority of trials of resistance modulators have
concentrated on patients with advanced disease due to resis-
tant tumours following intensive prior chemotherapy. How-
ever even at presentation a proportion of resistant tumour
cells are probably present and may be susceptible to modula-
tion. This hypothesis has subsequently been borne out by the
detection of P-glycoprotein positive cells in untreated
tumours in other tumour types (Goldstein et al., 1989). We
have therefore investigated the activity of verapamil as a
resistance modulator in previously untreated SCLC patients
in a large-scale, randomised trial. The major end-points of
this clinical study were to assess any possible enhanced nor-
mal tissue toxicity and to examine for an increased response
rate and/or improved survival.
Methods
Patient selection/demography
Patients with histologically proven small cell lung cancer
aged 70 or less and with ECOG performance status of 0, 1 or
2 were eligible. Assessment included a full clinical examina-
tion, with pulse and lying and standing blood pressure. A full
blood count and biochemical screen (urea, electrolytes and
liver function tests) were checked along with a pre-treatment
chest X-ray and bronchoscopy. All patients had adequate
bone marrow and hepatic function and had had no previous
chemotherapy or radiotherapy. Eligible patients had no
active cardiac disease, and had not been on beta-blocker or
prior calcium antagonist therapy. An ECG was performed at
each cycle (verapamil arm) along with regular standing and
lying blood pressure. All patients gave informed consent.
Registration, stratification, randomisation and data collection
Nine centres from the West of Scotland, one from Aberdeen
and also one from Northern Ireland entered patients into this
study under the auspices of the West of Scotland Lung
Cancer Research Group. Data collection was organised via
the West of Scotland Clinical Trials Office at the Beatson
Oncology Centre (Western Infirmary, Glasgow).
Treatment design
A widely recognised four-drug combination was used of
which doxorubicin, vincristine and etoposide are known to
be involved in resistance in the MDR phenotype. Cyclophos-
phamide, the fourth drug used in the chemotherapy protocol
is not associated with MDR (Pastan & Gottesman, 1987).
A dose of 480 mg verapamil (orally) per day was selected
as the maximum dose likely to avoid significant cardiovas-
cular side-effects on the basis of available literature (ABPI
Data Sheet Compendium, 1989). This dose would be
expected to give a plateau drug concentration of approx-
imately 1 .tM (with an equimolar concentration of nor-
verapamil). Patients randomised to receive verapamil, were
given verapamil 120 mg 6 hourly for a total of 5 days,
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beginning 2 days prior to chemotherapy to achieve steady-
state levels of verapamil at the time of chemotherapy. Cap-
sules were not routinely counted. Blood samples were
obtained during verapamil treatment from 18 patients from
one centre (see below).
Patients were treated with cyclophosphamide (750 mg m2
by i.v. bolus), doxorubicin (40 mg m-2 by i.v. bolus), vincris-
tine (1.4 mg m-2 by i.v. bolus) on Day 1 and etoposide
(75 mg m-2, as a 1 h intravenous infusion) on Days 1, 2 and
3 of chemotherapy. The control (no verapamil) patients were
not given placebo capsules.
Patients received four courses of chemotherapy repeated at
3 weekly intervals unless there was significant toxicity neces-
sitating withdrawal or there was evidence of disease progres-
sion. Patients who, at restaging after four courses, were felt
to have entered complete remission (see below), received
consolidation radiotherapy (4000 cGy in 15 fractions over 3
weeks), to the primary site(s) of thoracic disease and simul-
taneous prophylactic cranial irradiation (3000 cGy in ten
fractions over 2 weeks).
Dose modification
Chemotherapy was given at the above doses if on Day 1 the
white cell count (wbc) was > 3.0 x I09 1' and platelets were
> 100 X 109 1-'. If these values had not been reached, treat-
ment postponement was possible for up to 2 weeks before
necessitating removal from study.
If the nadir WBC was < 1.0 x 109 1` or if nadir platelets
were <30 x 1091-', the doses of cytotoxic drug in subse-
quent courses of chemotherapy were reduced by 20%.
Restaging andfollow-up studies
Full restaging was performed after completion of four cycles
of chemotherapy. This comprised repeat clinical (including
haematological and biochemical parameters) and radiological
examinations and repeat bronchoscopy in patients with com-
plete chest radiograph response. Survival was measured as
time from randomisation to time of death.
Verapamil levels
A total of 75 blood samples were obtained from 18 patients
(range 1-11 samples per patient), selected from the
verapamil treatment group, at various times during the 5 day
verapamil treatment period. Verapamil and norverapamil
concentrations in plasma were estimated by an HPLC assay
with fluorescence detection (Cole et al., 1981).
Statistical methods
The study was stratified for disease extent. The randomisa-
tion list was constructed using random permuted blocks of
length 6. Comparisons of pretreatment characteristics and
survival were based on all randomised eligible patients. All
other comparisons used randomised eligible patients who
started protocol treatment (see patient demography, Table I
below). Categorical variables were compared mainly using
Pearson's chi-square test (with no continuity correction).
Categories were combined if necessary to make all expected
values greater than or equal to 5. If it was not possible to
combine categories to make all expected values greater than
or equal to 5 then Fisher's exact test was used on the
appropriate 2 x 2 table. When overall response was com-
pared stratification according to disease extent was included
in the analysis and the P-values were calculated using the
Mantel-Haenszel test. The Mann-Whitney U-test was used
for the comparison of continuous variables such as age and
total cumulative dose. When pulse and blood pressure
measurements were compared before the after verapamil,
Wilcoxon's signed rank sum test was used. Kaplan-Meier
estimates were used for survival curves. Survival curves were
terminated when five patients were at risk. Survival was
measured from time of randomisation and all causes of death
have been included. Comparison on survival was by the
Mantel-Haenszel stratified log-rank test, with stratification
based on extent of disease. The study was designed to have
an approximately 80% chance of detecting a 50% difference
in median survival between the two treatment arms.
Results
Recruitment to this study is complete and a total of 226
patients have been entered. Six patients were found to be
ineligible soon after randomisation. Reasons for ineligibility
included patient refusal (1), death (1), hypotension (1),
already on beta blocker (1), already on verapamil (1) and
given verapamil in error (1).
In terms of disease extent, performance status, and the
prognostic indicators described by Souhami et al. (1985) no
significant differences were found between the two arms of
the study (Table I), and similar numbers of cycles of protocol
treatment were given in the verapamil and control arms
(P = 0.918). The majority of dose reductions were on account
of haematological toxicity. There were a similar number of
patients who stopped chemotherapy after two courses in both
treatment arms. There were a similar number of deaths (nine
in verapamil group, ten in control arm) during treatment.
The reasons for discontinuing chemotherapy and the causes
of death during treatment were similar in each treatment
arm.
The worst toxicity during any one patient's treatment was
recorded. There were no statistically significant differences in
general toxicities between the two arms, except for more
severe alopecia in the verapamil treatment group (P = 0.045)
(Table II). Constipation and tiredness (both side-effects of
verapamil) were not documented.
Table I Details of pre-treatment patient characteristics
Verapamil Control P-value
Age (median, range) 59 (35-70) 59 (37-69) 0.495
Performance status 0 22.5% ( 25)a 25.7% ( 28) 0.752
(ECOG) 1 65.8% ( 73) 65.1% ( 71)
2 11.7% ( 13) 9.2% ( 10)
100.0% (111) 100.0% (109)
Sex Male 55.9% ( 62) 59.6% ( 65) 0.571
Female 44.1% ( 49) 40.4% ( 44)
100.0% (111) 100.0% (109)
Disease extent Limited 75.7% ( 84) 74.3% ( 81) 0.815
Extensive 24.3% ( 27) 25.7% ( 28)
100.0% (111) 100.0% (109)
Souhami Good 28.1% ( 27) 29.5% ( 28) 0.827
categories Moderate 43.8% ( 42) 46.3% ( 44)
Poor 28.1% ( 27) 24.2% ( 23)
100.0% ( 96) 100.0% ( 95)
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Table II Toxicity (based on all randomised eligible patients who received at
least one course of protocol treatment). Figures in parentheses refer to the
actual number of patients
WHO grade Verapamil Control P-value
Nausea 0 9.9% ( 10) 5.7% ( 6) 0.553
1 29.7% ( 30) 30.5% ( 32)
2 25.7% ( 26) 23.8% ( 25)
3 33.7% ( 34) 36.2% ( 38)
4 1.0% ( 1) 3.8% ( 4)
100.0% (101) 100.0% (105)
Oral 0 71.0% ( 71) 77.7% ( 80) 0.528
1 19.0% ( 19) 15.5% ( 16)
2a 6.0%( 6) 3.9%( 4)
3a 3.0% ( 3) 2.9% ( 3)
4a 1.0%( 1) 0.0%( 0)
100.0% (100) 100.0% (103)
Haemorrhage 0 98.0% ( 98) 98.1% (101) 1.000b
la 1.0%( 1) 0.0%( 0)
2a 1.0%( 1) 1.0%( 1)
3a 0.0% ( 0) 0.0% ( 0)
4a 0.0%( 0) 1.0%( 1)
100.0% (100) 100.0% (103)
Alopeciac 0 7.1% ( 7) 9.5% ( 10) 0.045
1 1.0% ( 1) 5.7% ( 6)
2 11.1% (11) 20.0% ( 21)
3 36.4% ( 36) 36.2% ( 38)
4 44.4% ( 44) 28.6% ( 30)
100.0% ( 99) 100.0% (105)
Fever 0 88.8% ( 88) 93.2% ( 96) 0.203
la 9.0%( 9) 1.9%( 2)
2a 3.0% ( 3) 4.9% ( 5)
100.0% (100) 100.0% (103)
Neurotoxicity 0 64.7% ( 64) 64.1% ( 66) 0.978
1 29.3% ( 29) 29.1% ( 30)
2a 5.1%( 5) 4.9%( 5)
3a 1.1% ( 1) 1.9% ( 2)
100.0% ( 99) 100.0% (103)
Cardiac 0 98.0% ( 98) 96.1% ( 99) 0.683b
Ia 0.0% ( 0) 2.9% ( 3)
2a 1.0%( 1) 0.0%( 0)
3a 1.0%( 1) 0.0%( 0)
4a 0.0%( 0) 1.0%( 1)
100.0% (100) 100.0% (103)
aThese categories combined for calculating the P-value. "This P-value
obtained from Fisher's exact test. cModified WHO Grade: 0 = None,
1 = Minimal; 2 = Mild, not requiring wig, 3 = Moderate, requiring wig,
4 = Complete.
Apart from a small, but statistically significant, fall in
median systolic and median diastolic blood pressures after
the first course of treatment with verapamil [systolic BP 130
fell to 120, P<0.001; diastolic BP 75 fell to 70, P = 0.005] (a
similar pattern was seen with subsequent courses of chemo-
therapy), there was no evidence of increased cardiovascular
toxicity in the verapamil arm. One patient in the control arm
died of an acute myocardial infarction. One patient in the
verapamil treatment arm developed transient 1st degree A-V
block during the first course of verapamil, but this did not
prevent further treatment with verapamil and the heart block
did not recur.
There was no significant difference in haematological tox-
icity between the two treatment arms throughout the study.
Lowest median nadir blood count values occurred after Cycle
1 in both arms of the study. Haemoglobin (verapamil)
12.5 g dl-', haemoglobin (control) 12.4 gdl-', P = 0.557;
white cell count (verapamil) 1.6, white cell count (control)
2.0; P=0.065; platelets (verapamil) 165, platelets (control)
179, P = 0.646. There were significantly more dose reductions
after Course 1 in the verapamil treatment arm. Dose reduc-
tions occurred after course 1 in 21.4% of patients in the
verapamil arm and in 10.2% of patients in the control arm
(P = 0.031). Over all cycles there was no significant difference
in the incidence of dose reduction in the verapamil (29.9%)
and control (19.6%) arms of the study (P = 0.082).
Response data for all the 192 evaluable patients and for
the patients divided according to disease extent in each treat-
ment arm are shown in Table III. No statistically significant
differences in overall response were seen. A total of 22
patients were unevaluable for response (six did not start on
protocol treatment, three did not have response assessed and
13 died before 12 weeks assessment).
Survival curves for the patients, divided according to
disease extent at presentation and according to treatment
group (verapamil or control) are shown in Figure 1. As
expected, patients with extensive disease show a worse sur-
vival pattern. The analysis of the survival curves (based on
220 of the 226 patients) in terms of median survival and
death rate is shown in Table IV. This confirms that there is
no significant difference in survival between the verapamil
treatment and the control arms for the group as a whole
(P = 0.290). Also listed in Table IV are the causes of death.
There were no significant differences between the verapamil
and control arms. The majority of patients have died of
tumour progression.
Median verapamil concentration for the 18 patients studied
was 387 ng ml-l (0.85 JLM) with a wide inter-patient varia-
tion, range = 10-789 ngml-' and also significant intra-
patient variation. Median norverapamil concentration was
350ng ml-' (0.77Mm), range 10-985ngml-[.
Discussion
This is the first large-scale randomised study to examine the
feasibility and effects, in terms of toxicity, response and
survival, of adding a resistance modifier to combination816 R. MILROY
cytotoxic chemotherapy. There has been one published study
of resistance naodulation (using verapamil and tamoxifen) in
small cell lung cancer which showed that the initial response
rate was quite high for this group of patients (complete 24%,
overall 58%). Median survival was 46 weeks which compared
favourably with historic controls (Figueredo et al., 1990). A
group from Sydney, Australia, are also conducting a ran-
domised study of verapamil given in addition to
chemotherapy in small cell lung cancer and the study remains
in progress (Bell, 1990).
Table III Response data at 12 weeks are defined by WHO criteria
for all patients (CR = complete response, PR = partial response;
LD = limited disease, ED = extensive disease). The actual number of
patients are shown in parentheses
Verapamil Control
Responsea CR LD 42.5% (31) 31.9% (23)
ED 26.0% ( 6) 12.5% ( 3)
All 38.5% (37) 27.1% (26)
PR LD 39.7% (29) 51.4% (37)
ED 60.9% (14) 58.3% (14)
All 44.8% (43) 53.1% (51)
No change LD 9.6% ( 7) 6.9% ( 5)
ED 0.0% (0) 8.3% (2)
All 7.3% ( 7) 7.3% ( 7)
Progressive LD 8.2% ( 6) 9.7% ( 7)
Disease ED 13.0% ( 3) 20.8% ( 5)
All 9.4% ( 9) 12.5% (12)
Estimated difference in percentage of overall (CR + PR) responders
(Verapamil-Control) = 3.1%b 95% c.i. for above difference
= - 8.1% to 14.3%. aExpressed as percentage of evaluable patients.
'This differense is calculated allowing for the stratification on disease
extent.
Extensive disease
o VERAPAMIL
I CONTROL
Limited disease
* VERAPAMIL
4 CONTROL
2
Time (years)
Figure I Actuarial survival curves for study patients, divided
according to disease extent (limited or extensive) and treatment
group (verapamil or control).
As P-glycoprotein has been shown to be present in normal
tissues (Fojo et al., 1987; Thiebault et al., 1987) this has
possible implications for the use of verapamil in addition to
chemotherapy. In terms of impact on myelosuppression, in
vitro (Fine et al., 1987; Yalowich et al., 1985) and pilot
clinical studies (Benson III et al., 1985; Dalton et al., 1989;
Miller et al., 1988; Ozols et al., 1987; Presant et al., 1986)
indicate that no enhancement resulting from modifier is likely
to occur, in keeping with the observation that P-glycoprotein
is not normally expressed at high levels in bone marrow
(Sugawara et al., 1988).
However it has previously been reported that verapamil
can increase plasma levels of doxorubicin and reduce doxo-
rubicin clearance (Kerr et al., 1986). Thus a pharmaco-
kinetic effect might explain the increased alopecia and lower
nadir white cell counts after the first course ofchemotherapy
in the patients in this study treated with verapamil. In this
regard the greater incidence of dose reductions after the first
course of chemotherapy in the verapamil arm patients is
interesting. This presumably related to the lower nadir white
cell counts after Course 1, and may account for the lower
total cumulative dose of cyclophosphamide noted in the
verapamil arm (median 2.5 gm in verapamil arm cf. median
2.7gm in control arm; P = 0.106).
There was no evidence of increased cardiovascular toxicity
caused by verapamil in this study and this presumably
related to the relatively low oral dose, with consequently low
plasma verapamil levels as previously documented by Kerr et
al. (1986). The levels achieved in patients in that study are
well below those optimally active in vitro (over 3000 ng ml-l,
6.6,UM). However similar levels of norverapamil were also
achieved and, at least in vitro, verapamil and norverapamil
have been shown to have an additive effect in terms of
resistance modulation (Merry et al., 1989). Thus total levels
of active modifier achieved in the clinic (1.6JlM) are at least
approaching concentrations known to be active in vitro.
There were no statistically significant differences in res-
ponse in the two arms of the study (Table III). There was no
statistically significant difference in survival noted between
the treatment (verapamil) and control arms in this study.
Although the majority (75%) of patients had limited disease,
only 29% fell into Souhami's good prognosis category
(Souhami et al., 1985). Thus the median survival of only
45-48 weeks in the limited disease patients in this study is
not unexpected. In patients with extensive disease the
difference in median survival between the verapamil arm (32
weeks) and the control arm (23 weeks) was more favourable
than for patients with limited disease but did not achieve
statistical significance.
Thus, in terms of response and survival, overall results in
both treatment arms are similar, even though there were
more dose reductions in the verapamil treated patients after
the first course of chemotherapy. Verapamil may therefore
have had some effect and it is possible that with higher
plasma levels one might anticipate greater resistance modify-
ing activity particularly as we have demonstrated a dose
Table IV Survival data and causes of death
Disease No. of No. of Median 95% c.i. for
Arm status patients deaths survival median survival
Verapamil Limited 84 75 45 weeks 35-52 weeks
Control Limited 81 62 48 weeks 44-56 weeks
Verapamil Extensive 27 25 32 weeks 24-48 weeks
Control Extensive 28 24 23 weeks 18-31 weeks
Verapamil All 111 100 41 weeks 36-48 weeks
Control All 109 86 44 weeks 36-49 weeks
Relative death rate (Verapamil/Control) = 1.17 P = 0.290
95% c.i. for relative death rate = 0.87-1.57
Causes of death Verapamil Control
Drug toxicity 6 3
Tumour progression 86 73
Non-cancer cause (without tumour) 0 1
Non-cancer cause (with tumour) 3 4
Not known 5 5
100.
80-
60 -
40 -
a)
0
U) 0~
20
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response effect in vitro (Plumb et al., 1990). Such an
approach is however limited by cardiovascular toxicity (Ozols
et al., 1987). It is known that the L-isomer of verapamil is
about ten times more effective as a calcium antagonist than
the D-isomer (Ferry et al., 1985). However the two isomers
are equipotent blockers of the fast inward current (Newrath
et al., 1981). Since the effects of verapamil on drug resistance
do not appear to relate to calcium antagonism (Ramu et al.,
1984) it is conceivable that the D-isomer alone would be a
more suitable agent to use clinically in view of the potential,
though yet undemonstrated, reduction in cardiovascular side-
effects compared to the racemic mixture. Moreover the D-
stereoisomer has been shown to be equally active in terms of
resistance modification in SCLC in vitro (Plumb et al., 1990).
Thus use of D-verapamil alone might be a useful approach in
future clinical studies of resistance modulation. However,
recent work using human tumour biopsies and cell lines now
suggests that the P-glycoprotein-mediated (MDR) mechanism
of resistance is unlikely to be the major factor in the drug
resistance seen in small cell lung cancer (Lai et al., 1989).
Despite this, resistance modulation with verapamil in small
cell lung cancer cell lines can still occur (Cole et al., 1989),
raising the possibility of an alternative mechanism of action
for this particular modulating agent (Plumb et al., 1989).
The failure to achieve a more substantial effect in this
study may relate to the low blood levels of verapamil seen in
the clinic or to the presence of other cellular mechanisms by
which drug resistance develops. Further studies of resistance
modulation in small cell lung cancer should perhaps employ
a combination of agents, especially those where effective
concentrations can be more easily achieved in the clinic. Such
studies should be based on careful analysis of the
mechanisms by which modulation occurs in vitro.
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